Migraine
Conditions
Interventions
Lu AG09222 or placebo matching to Lu AG09222 will be administered by SC injection.
Sponsors
Yazawa Masanari
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit. -The participant has a history of migraine onset more than or equal to 12 months prior to the Screening Visit. -The participant has a migraine onset at less than or equal to 50 years of age. -The participant has more than or equal to 4 migraine days per month for each month within the past 3 months prior to the Screening Visit. -The participant has documented evidence of treatment failure in the past 10 years of at least 2 to 4 (maximum) different migraine preventive medications.
Exclusion criteria
Exclusion criteria: -The participant has previously been dosed with an anti-pituitary adenylate cyclase-activating peptide (anti-PACAP treatment). -The participant has confounding and clinically significant pain syndromes. -The participant has a diagnosis of acute or active temporomandibular disorder. -The participant has a history or diagnosis of confounding headaches.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change From Baseline in the Number of Monthly Migraine Days (MMDs) | — |
Countries
Bulgaria, Czech Republic, Denmark, France, Georgia, Germany, Hungary, Japan, Lithuania, Poland, Romania, Slovakia, Spain, US
Contacts
Public ContactClinical trial contact
ICON Clinical Research GK
Outcome results
None listed